SotyKtu
Amgen’s Otezla holds its ground against BMS’ Sotyktu in oral plaque psoriasis market, leaving room for J&J’s potential game-changer
Anika Sharma
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
Sotyktu, a campaign by Bristol Myers Squibb to provide “clear understanding” of living with psoriasis, launches
SG Tylor
Source – Bristol Myers Squibb Bristol Myers Squibb is striving to provide a comprehensive insight into the challenges of living ...
BMS’ Sotyktu is approved for psoriasis usage by the NHS
SG Tylor
Source: Bristol-Myers Squibb Just weeks after receiving approval in the UK, Bristol-Myers Squibb’s novel oral therapy for psoriasis, SotyKtu, has ...
